Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label study with daily doses up to 144 mg/day Strattera (atomoxetine) in the
treatment of adults with attention deficit hyperactivity disorder not otherwise specified.
The researchers hypothesize ADHD symptomatology in adults with ADHD NOS will be responsive to
Strattera treatment and Strattera treatment (in doses of up to 120 mg/day or 1.5 mg/kg/day,
whichever is less) in adults with ADHD NOS will be safe and well tolerated.